Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Angiogenesis depends upon EPHB4-mediated export of collagen IV from vascular endothelial cells
Di Chen, Elizabeth D. Hughes, Thomas L. Saunders, Jiangping Wu, Magda N. Hernandez Vasquez, Taija Makinen, Philip D. King
Di Chen, Elizabeth D. Hughes, Thomas L. Saunders, Jiangping Wu, Magda N. Hernandez Vasquez, Taija Makinen, Philip D. King
View: Text | PDF
Research Article Angiogenesis Vascular biology

Angiogenesis depends upon EPHB4-mediated export of collagen IV from vascular endothelial cells

  • Text
  • PDF
Abstract

Capillary malformation-arteriovenous malformation (CM-AVM) is a blood vascular anomaly caused by inherited loss-of-function mutations in RASA1 or EPHB4 genes, which encode p120 Ras GTPase-activating protein (p120 RasGAP/RASA1) and Ephrin receptor B4 (EPHB4). However, whether RASA1 and EPHB4 function in the same molecular signaling pathway to regulate the blood vasculature is uncertain. Here, we show that induced endothelial cell–specific (EC-specific) disruption of Ephb4 in mice resulted in accumulation of collagen IV in the EC ER, leading to EC apoptotic death and defective developmental, neonatal, and pathological angiogenesis, as reported previously in induced EC-specific RASA1-deficient mice. Moreover, defects in angiogenic responses in EPHB4-deficient mice could be rescued by drugs that inhibit signaling through the Ras pathway and drugs that promote collagen IV export from the ER. However, EPHB4-mutant mice that expressed a form of EPHB4 that is unable to physically engage RASA1 but retains protein tyrosine kinase activity showed normal angiogenic responses. These findings provide strong evidence that RASA1 and EPHB4 function in the same signaling pathway to protect against the development of CM-AVM independent of physical interaction and have important implications for possible means of treatment of this disease.

Authors

Di Chen, Elizabeth D. Hughes, Thomas L. Saunders, Jiangping Wu, Magda N. Hernandez Vasquez, Taija Makinen, Philip D. King

×

Figure 9

Reduced B16 melanoma growth in adult induced EPHB4-deficient mice associated with impaired tumor angiogenesis.

Options: View larger image (or click on image) Download as PowerPoint
Reduced B16 melanoma growth in adult induced EPHB4-deficient mice associ...
Adult TM-treated Ephb4fl/fl and Ephb4fl/fl Ubert2cre mice were injected in flanks with B16 melanoma cells and tumors were harvested 13 days later. Some mice received 4PBA at the same time as the tumor and on all subsequent days until tumor harvest. (A) Representative images of explanted tumors. (B) Plot shows tumor weights at day 13. Bars represent mean ± 1 SEM tumor weight (Ephb4fl/fl TM alone, n = 14; Ephb4fl/fl Ubert2cre TM alone, n = 18; Ephb4fl/fl TM + 4PBA, n = 12; Ephb4fl/fl Ubert2cre TM + 4PBA, n = 18). (C) Sections of explanted tumors were stained with anti-CD31 antibodies to identify BVs. Shown are representative images. (D) Plot shows percentage BV coverage of randomly selected 200 × 200 μm areas of tumors. Bars represent mean ± 1 SEM percentage BV coverage (Ephb4fl/fl TM alone, n = 26; Ephb4fl/fl Ubert2cre TM alone, n = 27; Ephb4fl/fl TM + 4PBA, n = 18; Ephb4fl/fl Ubert2cre TM + 4PBA, n = 35). *, P < 0.05; **, P < 0.01; ****, P < 0.0001; 1-way ANOVA with Tukey.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts